Clinical trial
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects…
NCT00036062 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00036062 |
|---|---|
| Title | A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury |
| Official title | A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Distress Syndrome, Adult, Acute Lung Injury |
| Intervention type | Drug |
| Interventions | Sivelestat |
| Enrollment | 600 |
| Start date | Aug 1, 2001 |
| Completion | Dec 1, 2002 |
| First posted | May 8, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | Australia, Belgium, Canada, New Zealand, Spain, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: